Compare Fortinet Inc (FTNT) vs Gilead Sciences, Inc. (GILD) Price & Performance

Fortinet (FTNT) trades at $159.64, down 0.29% on the day, with a bullish technical signal from moving averages and a consensus price target of $174.50. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.90 surpassing the $0.746 expectation. Revenue growth remains robust, climbing to $6.80 billion in 2025, while net income margins exceed 28%. Positive media coverage highlights strong AI-driven cybersecurity demand and platform expansion.

Outlook is favorable given earnings momentum and industry tailwinds, but high valuation ratios (P/E of 56.41) pose a risk if growth slows. Investor sentiment is supported by analyst buy ratings (42.65%) and institutional accumulation, though competitive pressures and macroeconomic volatility require monitoring.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.